Xilio Therapeutics Inc. (XLO)
$9.00
$-0.03
(-0.33%)
As on 16-Sep-2026 11:10EDT
Market cap
$59 Mln
Revenue (TTM)
$64 Mln
P/E Ratio
--
P/B Ratio
0.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.6 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1.8
-
Face value
--
-
Shares outstanding
6,580,153
5 Years Aggregate
CFO
$-279.03 Mln
EBITDA
$-310.37 Mln
Net Profit
$-310.53 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Xilio Therapeutics (XLO)
| 0.4 | -1.9 | 7.9 | -14.5 | -35.2 | -- | -- |
|
BSE Sensex
| -12.2 | -4.7 | -2.5 | -9.1 | 3.1 | 4.8 | 10.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Xilio Therapeutics (XLO)
| -33.0 | 72.9 | -79.6 | -83.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Xilio Therapeutics (XLO)
|
9.0 | 58.8 | 64.1 | -21.8 | -34.1 | -40.6 | -- | 0.8 |
| 67.4 | 11,702.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 25.1 | |
| 70.2 | 10,255.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 57.7 | 13,905.5 | 2,435.9 | 860.6 | 31.0 | 43 | 17.6 | 7.5 | |
| 109.6 | 12,167.0 | 1,663.7 | 413.6 | 36.3 | 430 | 31.4 | 84.6 | |
| 344.3 | 10,270.8 | 440.5 | 241.5 | 33.4 | 18.7 | 43.3 | 7.6 | |
| 528.2 | 12,348.9 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 23.5 | |
| 620.6 | 16,398.7 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.5 | 37.5 | |
| 124.0 | 9,808.7 | 0.0 | -450.1 | -- | -44.6 | -- | 8.4 | |
| 314.5 | 9,341.5 | 0.0 | -339.1 | -- | -30.6 | -- | 7.0 |
Shareholding Pattern
View DetailsAbout Xilio Therapeutics (XLO)
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic... non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts. Read more
-
President, CEO & Director
Dr. Rene Russo BCPS, Pharm.D.
-
President, CEO & Director
Dr. Rene Russo BCPS, Pharm.D.
-
Headquarters
Waltham, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Xilio Therapeutics (XLO)
What is the current share price of Xilio Therapeutics Inc (XLO) Today?
The share price of Xilio Therapeutics Inc (XLO) is $9.00 (NASDAQ) as of 16-Sep-2026 11:10 EDT. Xilio Therapeutics Inc (XLO) has given a return of -35.18% in the last 3 years.
What is the current PB & PE ratio of Xilio Therapeutics Inc (XLO)?
Since, TTM earnings of Xilio Therapeutics Inc (XLO) is negative, P/E ratio is not available.
The P/B ratio of Xilio Therapeutics Inc (XLO) is 0.82 times as on 11-Sep-2026, a 83 discount to its peers’ median range of 4.92 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-1.53 |
1.52 |
2024 |
-0.08 |
0.25 |
2023 |
-0.01 |
0.03 |
2022 |
-0.84 |
0.70 |
2021 |
-0.31 |
0.12 |
What is the 52 Week High and Low of Xilio Therapeutics Inc (XLO)?
The 52-week high and low of Xilio Therapeutics Inc (XLO) are Rs 104.47 and Rs 6.47 as of 17-Sep-2026.
What is the market cap of Xilio Therapeutics Inc (XLO)?
Xilio Therapeutics Inc (XLO) has a market capitalisation of $ 59 Mln as on 11-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Xilio Therapeutics Inc (XLO)?
Before investing in Xilio Therapeutics Inc (XLO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.